Zydus Lifesciences launches cancer drug Lenalidomide in US
Ahmedabad: Drugmaker, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has recently announced that the company has launched Lenalidomide Capsules in the US.
The company had earlier received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength. USRLD: Revlimid.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, go beyond their usual boundaries to invade adjoining parts of the body and/or spread to other organs.
The medicine is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS).
The drug is being manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India. Lenalidomide had annual sales of USD 2.86 bn in the United States, according to IQVIA MAT July 2022.
Read also: Zydus Lifesciences US arm secures USFDA nod for Sugammadex Injection
Medical Dialogues team had earlier reported that Zydus Lifesciences had received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials (USRLD: Alimta). Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma.
Read also: Zydus Lifesciences Chemotherapy drug Pemetrexed gets USFDA okay
Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
Read also: Zydus Lifesciences US arm bags USFDA nod for schizophrenia drug Cariprazine
